In his new role, John Fowler will take charge of the company’s global operations. He has also been assigned the R&D portfolio wherein he will ensure that the firm’s customers receive unique and excellent services.
Mumbai/India — Piramal Pharma Solutions (PPS), part of Piramal Enterprises, has recently announced the appointment of John Fowler as its Chief Operating Officer. PPS is a leader in integrated contract development and manufacturing, with a global network of 12 development and manufacturing facilities across North America, Europe and Asia. The company offers a comprehensive range of services including drug discovery solutions, process & pharmaceutical development services, clinical trial supplies and commercial supply of APIs and finished dosage forms.
As Chief Operating Officer, Fowler will be responsible for Global Operations and R&D, and will play a lead role in ensuring that its customers consistently experience differentiated and excellent levels of service.
On announcing the appointment, Vivek Sharma, CEO, Piramal Pharma Solutions said, “As PPS enters into the next phase of its rapid growth, it is important that we bring in seasoned executives with international experience and expertise. Over a distinguished career of nearly three decades, Fowler has successfully led several global businesses, streamlined operations, developed and implemented commercial strategies that have increased profitability while driving growth, and has an aligned focus on R&D teams with long term business requirements. With our customers increasingly choosing Piramal as their ‘Partner of Choice’ to progress their assets from discovery towards commercialization, his track record of aligning services and talent towards a common vision, is one that the PPS team can benefit from. We are excited to have Fowler as part of our Leadership team, welcome him, and look forward to his contributions in building strategic partnerships with our customers and propel PPS forward into the next decade.”
Most recently, Fowler served as the Divisional CEO of the Global Fine Chemicals business at Johnson Matthey (JM), with responsibility for JM’s services (Custom API development, manufacturing, catalyst & Chiral technologies), and products (Generics development and manufacturing) portfolio. Before leading JM’s Fine Chemical Division, he also held senior leadership roles in several business verticals at JM, including pharmaceutical materials and services, environmental catalysts and technologies, among others. Fowler has a Chemical Engineering degree from Bucknell University and an MBA from St. Joseph University.